How Manish Gupta Built Indegene Into a $223M Pharma Giant Without Playing the VC Game
The IIM Ahmedabad graduate turned a $400K seed round into a quarter-billion dollar business by saying no to easy money, surviving the dot-com crash, and preparing for pharma's digital transformation.
In 2016, Manish Gupta did something almost unthinkable in India’s startup ecosystem. With $52 million in revenue, solid profitability, and term sheets from top-tier venture capital firms on his desk, the co-founder and CEO of Indegene walked away from the deal.
“While we had firm term sheets, we realized it’s not going to be fair to get a new investor when you’ve told a story and then you realize you’ve got to do all this stuff.”
Manish recalls. The “stuff” he’s referring to was a major internal restructuring, shutting down business units, and doubling down on digital capabilities. Actions that would slow growth in the near term, exactly what new investors wouldn’t want to hear.
This decision encapsulates everything about Indegene’s 25-year journey: patient capital, institutional discipline, and a willingness to play the long game when everyone else is sprinting.
Check out the video of the conversation here or read on for insights.
Today, Indegene serves 85+ global pharmaceutical companies with $223 million in annual revenue. The company is preparing for an IPO targeting ₹3,200 crore from public markets, a validation of a contrarian approach to company building that prioritized profitability over growth-at-all-costs.
The Restless Founder and the Medical-Tech Thesis
Manish’s entrepreneurial journey began with restlessness. After graduating from IIM Ahmedabad in 1998, he joined ANZ Grindlays Bank, then moved to Infosys just five days before their ADR listing. The company had crossed $100 million in revenue and employed 3,000-4,000 people.
He left in eight and a half months.
“There was a restlessness,” he explains. “That whole thing of doing things step by step, I just wanted to do much more. And you realize that in a corporate setup, after some time, that becomes very difficult.”
The year was 1999, and India’s first dot-com wave was building. But Manish and his co-founder, Dr. Radhakrishna Nair (a medical doctor and IIM Ahmedabad senior who had worked at Sarabhai Labs), weren’t interested in building another IT services firm. They had a different thesis.
“We thought we could build a firm which has the DNA of really interweaving medical and technology capabilities together to solve various problems in healthcare. Tech guys don’t understand the medical domain, which is a very nuanced domain. The risks are much higher if you go wrong. And medical guys don’t understand the technology domain.”
Inspired by innovations like the Palm Pilot for doctors and Jim Clark’s Healtheon, they envisioned a physician-focused platform that would become a “one-stop shop” for medical information. In 2000, they raised $350,000-$400,000 from Ant Factory, a British venture capital firm making its first investment in India.
Surviving the Dot-Com Crash
By late 2000, the dot-com bubble was deflating rapidly, and Indegene was running out of cash. The founders hadn’t taken salaries for almost two years.
“It was very clear to us that either we packed and went back home and looked for jobs, or did something completely different,” Manish says. “We decided that we will very quickly monetize whatever we have built. And monetize was not just generating revenues, you had to generate profits and cash flows because depending on external funding was not going to be easy.”
The pivot was surgical. Instead of building a B2C platform, they went straight to B2B. They had built relationships with leading academic centers like AIIMS and PGI, secured content rights from major medical conferences, and developed an internal team capable of creating medical education content.
The initial model: sell conference content and medical education programs directly to doctors via CDs (online wasn’t viable in 2001 India). Then pharma companies noticed something unusual.
“Nobody in India likes to pay for content. But when pharma saw that there’s a queue of doctors who are paying advance for content they will get six weeks later, they came back saying, ‘Instead of doing this selling to doctors, why don’t you sell this to us? We will use our reps to distribute this content.”
The revenue trajectory tells the survival story: ₹25 lakhs in March 2001, then ₹2.2 crore in 2002, ₹4.4 crore in 2003, and ₹7 crore in 2004. They were profitable, but barely. Indian pharma companies had terrible payment cycles, creating constant cash flow stress.
In 2008, The Lancet recognized Indegene as one of the most credible sources of medical information in the region.
The US Gamble and the Acquisition From Hell
By 2004-05, Indegene faced a strategic question: stay in India with modest growth, or swing for the global market? The US represented over 50% of the world’s pharma market. If they wanted to build something significant, they had to be there.
Enter N.S. Raghavan, one of the co-founders of Infosys who had retired and set up a family office. Impressed by their grit and domain focus, he led a capital restructuring in 2005. With this capital, Indegene acquired a US company almost twice their size that offered medical education and scientific sales training for pharma reps.
On paper, it was perfect. In reality, it nearly killed the company.
“We had a torturous childhood which shaped us as a company. This company we acquired, we figured out we missed some things in diligence. It was a combination of inexperience and a bunch of other things. There were delivery issues with some big clients which were not identified during the diligence process.”
The company was losing money, had unhappy clients, and disputed invoices. The thesis had been to take three years to integrate and turn it around. Instead, they had months.
Manish and his co-founders took drastic action. They let go of the entire US management team and took direct control. They compressed a three-year capability-building roadmap in India into six to nine months. They shut down the Bombay and Delhi offices and centralized everything in Bangalore to ensure consistent quality standards.
They invested heavily in training, bringing experts from the US to India to train medical writers and illustrators, domains that didn’t exist in India at scale. They set up a business excellence team and robust HR practices when they were still just a ₹7 crore revenue company.
By 2008-09, they had stabilized at approximately $9 million in revenue, profitable with stable teams.
The Digital Bet: Building Before the Market Was Ready
Between 2009 and 2010, pharma was going through massive changes. Close to $200-250 billion worth of products were going off-patent. Regulatory pressure was intensifying after scandals involving drugs like Vioxx and Avandia. The Sunshine Act mandated that any payment to physicians over $100 had to be publicly disclosed.
For Indegene, this created an opening. There were three obvious service categories to pursue: CROs (clinical trials), ad agencies, and CSOs (contract sales organizations providing reps to pharma). They evaluated all three and made contrarian calls.
CROs: Despite India being hot for clinical trials, they passed.
“If you don’t see how we could differentiate, we have no interest in being the 101st clinical trial company in India.”
Ad Agencies: Too entrenched, wouldn’t be credible from Bangalore.
CSOs: Attractive, but they decided on a variation. Instead of a Contract Sales Organization, they would be a Virtual Sales Organization.
“Our thesis was that sales and marketing and commercialization processes in pharma will change on the back of technology, broadly the word which was ‘digital.’ That’s the bet we took in 2009-2010. One of the channels could be a rep, but it’s just one of the channels.”
The model: reach physicians through websites, calls, emails, programmatic media, and analytics. Use data to profile physicians and determine the optimal mix of channels for each doctor. The loaded cost of a pharma rep in the US was already north of $250,000. Digital channels could achieve similar engagement at a fraction of the cost.
In 2012, they acquired a well-known Canadian company specializing in digital physician engagement to serve as their US front end. They started winning deals, first in emerging markets, then gradually in the US and Europe.
Walking Away From Easy Money
By 2016, Indegene had reached $52 million in revenue and was solidly profitable. The original plan was to raise a PE round in 2020, but they decided to test the market early. The process went well with firm term sheets from institutional investors.
But then they noticed something. The internal presentations from pharma clients had changed. Digital was no longer tactical, it was appearing in board-level strategy documents as a fundamental transformation priority, driven by the success of FANG companies.
“When we saw that, it was very evident to us that we just got to focus on this piece,” Manish recalls. But focusing meant restructuring. They had started a healthcare providers business in 2014 that was now floundering. They needed to shut down units, rehash capabilities, and double down on digital investments. This would slow near-term growth.
The founders unanimously agreed: it wouldn’t be fair to bring in investors and then immediately pivot. NSR, their long-time investor, supported the decision. They withdrew from the PE process entirely.
Over the next few years, they executed the restructuring. They acquired a European digital consulting firm in 2019. All acquisitions between 2012 and 2019 were funded from internal accruals.
The COVID Catalyst and Going Public
When COVID-19 hit in March 2020, Indegene drew down all credit lines and sat on cash. Then something unexpected happened. Their customers started doing more, not less.
Pharma had no choice. In-person sales calls were impossible. If they wanted to continue commercializing products, they had to go digital.
“When people used to ask me, what is the biggest blocker for you, I said digital adoption in life sciences companies,”
Manish explains.
“You can influence it a little bit by doing thought leadership, but you can’t bend the curve for a $1.5 trillion industry. You’ve got to be prepared when the curve bends. We realized the curve was bending in 2020.”
Indegene found itself uniquely positioned with over a decade of digital pharma commercialization experience. The business grew significantly between 2020 and 2022.
In early 2021, they brought in institutional capital. Carlyle Group and Brighton Park Capital invested approximately ₹1,500 crore at a valuation just below unicorn status. Twenty-one years after founding, Indegene had its first major institutional investors beyond NSR.
What Indegene Actually Does
To understand Indegene’s $223 million business, you need to understand pharma’s cost structure. Pharmaceutical companies spend 20-30% of their revenue on sales and marketing. For a $1.6 trillion global industry, that’s $320-480 billion annually. Historically, this spend has been fragmented across hundreds of vendors per company.
Pharma’s response has been centralization. Create “centers of excellence” that serve multiple brands across countries. Partner with 3-5 strategic vendors instead of 500. This is where Indegene wins.
They offer four main service lines:
Enterprise Commercial (35%+ of revenue): Content and campaign development across 35+ markets. Omnichannel activation through web, email, programmatic ads, and selective reps. Platform management for Salesforce and Veeva.
Enterprise Medical (25%+ of revenue): Global label management (one top-5 pharma client came to them after an audit revealed 40-45% compliance, a massive risk). Medical-legal review, medical affairs support, and pharmacovigilance.
Omnichannel Activation/VSO (25%+ of revenue): The original virtual sales model. Using data to map patient journeys and physician behaviors, then orchestrating optimal channel mix. Top physicians get reps, middle tier gets intensive digital, bottom tier gets awareness campaigns.
Digital Clinical Trials (small but growing): Protocol design using real-world evidence. Patient recruitment via digital channels (critical for rare diseases where finding patients is the bottleneck). Not full CRO operations, just the pieces where digital and data add value.
The differentiation comes from three sources: medical-tech DNA that pure agencies or tech firms can’t replicate, 40-50% cost advantage from Bangalore delivery with FDA-auditable quality, and digital-native capabilities built since 2010 rather than retrofitted.
On AI, Manish is pragmatic. “None of these are driverless cars today,” he explains.
“There are different levels of automation which have been introduced to reduce human effort, reduce errors, increase compliance, but the capability needs to sit alongside this.”
The approach is augmentation, not automation. AI handles pattern matching and data processing, humans handle judgment and regulatory accountability.
The Long Game
Looking back at 25 years, Manish distills the entrepreneur’s core responsibilities:
“First, identify opportunities where you can build businesses. But while identifying those opportunities, you’ve got to be really critical about how the market is going to shape up. Many times we as entrepreneurs have more wishful thinking about how things are going to change and the pace they’re going to change, than what reality is. Be more real if you’re building an enduring business.”
“Second, build teams, build processes, build institutions which can execute on that opportunity. Being entrepreneurial and thinking about institutions, being prudent, they conflict. You’ve got to find the right balance.”
This balance explains decisions that seemed counterintuitive: becoming profitable in 2001 instead of chasing growth, shutting down offices to centralize quality, saying no to the CRO trend despite VC money flowing, walking away from PE funding in 2016, waiting until year 21 to take institutional capital.
Each decision prioritized long-term institution building over short-term gains.
The validation is arriving. From ₹25 lakh in 2001 to $223 million in 2024. From bootstrapped survival to a ₹3,200 crore IPO. The timing is favorable: pharma is consolidating vendors, digital transformation is accelerating, and the funding winter has made profitability attractive again.
As Bill Gates said, “You always overestimate what you can do over a two-year period and always underestimate what can be done over a ten-year period.”
In Indegene’s case, it took 25 years. But the compounding worked.
Listen now!
Other Ways to Listen:
Before you go……the analytics only tell me so much, I want to hear what you feel and think about the conversations.
Mail me at ad@thepodium.in with your comments & feedback or if you just want to hear my comments on your startup idea - I love getting your emails!
Until the next founder's thesis📕,
Your host, AD